They reported significantly increased YKL-40 levels in AD and sporadic CJD patients, concluding that increased YKL-40 is a disease-specific marker of neuroinflammation and that it might have a potential for application in the evaluation of therapeutic intervention in dementias with a neuroinflammatory component. This evidence concerns the gene CHI3L1 and Alzheimer disease.